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Abstract

Introduction

Background: Lung cancer is a leading cause of death in United
States. A recent study using low dose CT scans for screening long
term smokers for lung cancer has, for the first time, demonstrated
reduction in mortality, although it is not a standard of care in the
community yet.

Lung cancer is a leading cause of death in the United States,
and it accounts for more deaths each year than breast, colon and prostate cancer combined. Screening studies in the
1980’s with chest x rays with or without cytological analysis
of sputum did not show any impact on lung cancer specific
mortality from screening high risk patients [1, 2]. Although a
recent study using low dose CT scans of the chest in patients
with higher risk factors for screening demonstrated reduction in mortality [3], this is not the current standard of care in
the community. Based on current medical knowledge, only
stage I lung cancer has successful cure numbers [4, 5], and a
screening method capable of detecting these cases early may
have a higher chance, of any method presently available, to
be accepted as standard of practice.
We did a study to see if there is a significant difference
in the stages of lung cancer at presentation diagnosed in 3
different institutions of the same health system. Geographically located in a 15 mile radius, but represented by different
racial, ethnic and socioeconomic groups, these institutions
could represent a microcosm of lung cancer. Significant differences would be interesting as it could shed light on current standard practices, those who detect lung cancer earlier
or practices that other hospitals are “not doing” and thereby
detecting lung cancer later. This could lead to greater mortality and morbidity, because of presentation at later stages of
the disease. This analysis could help identify the areas which
would benefit from possible screening or other preventive
approaches.

Methods: We analyzed lung cancer data for stages 0 through 4 for
1,412 individuals from, a public hospital, Nassau University Medical Center (NUMC) with patients of lower income, two private hospitals, North Shore University Hospital (NSUH) and Long Island
Jewish Hospital (LIJ), with patients of higher income, with average
household income per year of 83,795 $, 152,777 $ and 93,234 $
respectively.
Results: Significantly smaller percentages of patients were diagnosed with stages 0 and 1 lung cancer at NUMC (8.55%) versus
either NSUH (36.18%, P < 0.001) or LIJ (35.70%, (P < 0.001).
Conclusions: At this point there is evidence that Lung Cancer
Screening reduces mortality in long term smokers, but there is debate over, if it should be made into a recommendation. In light of
the above study we suggest, that screening for lower socioeconomic
class, could be recommended, if not for general population.
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Methods
We obtained retrospective data from 3 hospitals: Nassau
University Medical Center-NUMC (years 2000 - 2009),
Long Island Jewish Medical Center- LIJ (years 2007 - 2008)
and North Shore University Hospital-NSUH (years 2007 2008), which are parts of the same health system. We obtained tumor registry summary data for frequency of total
lung cancer diagnosed at different stages. The three hospitals
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31.91% (112)

59.54% (209)

8.55% (30)

91.45% (321)

12.55% (30)

87.45% (209)

Stage 2-3

Stage 4

Stage 0-1

Stage 2-4

Stage 0-1

Stage 4

51.57% (262)

48.43% (246)

63.82% (434)

36.18% (246)

38.53% (262)

25.29% (172)

36.18% (246)

NSUH % (#)

49.06% (131)

50.94% (136)

64.30% (245)

35.70% (136)

34.38% (131)

29.92% (114)

35.70% (136)

LIJ % (#)

59.54% (38,579)

40.46% (26,217)

73.31% (72,000)

26.69% (26,217)

39.28% (38,579)

34.03% (33,421)

26.69% (26,217)

US % (#)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

NUMC vs. LIJ

NUMC vs. NSUH

< 0.001

P-value

P-value

NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States.

8.55% (30)

NUMC % (#)

Stage 0-1

Variable

Table 1. Sample of Non-Small Cell Cancers

< 0.001

< 0.001

< 0.001

NUMC vs. US

P-value
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Figure 1. Sample of Non Small Cell Cancers. Vertical axis: percentage of total patients diagnosed in various stages; Horizontal axis: Stage of Lung Cancer; NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ:
Long Isiand Jewish Hospital; US: United States.

serve patients of different economic strata: NUMC patients
have an average household income of $ 83,795 per year and
average house cost of $ 385,610 and 27% minority population; LIJ patients have an average household income of $
93,234 per year and average house cost of $ 481,700 and

36% minority population; and NSUH patients have an average household income of $ 152,777 per year, average house
cost of $ 999,390 and 20% minority population.
As appropriate, Pearson chi-square analyses were used
to compare differences, unless there was a smaller sample

Table 2. Sample of Those With Adenocarcinoma

Variable

NUMC % (#)

NSUH % (#)

LIJ % (#)

Stage 0-1

9.90% (10)

45.24% (176)

40.96% (77)

Stage 2-3

24.75% (25)

20.57% (80)

28.19% (53)

Stage 4

65.35% (66)

34.19% (133)

30.85% (58)

Stage 0-1

9.90% (10)

45.24% (176)

40.96% (77)

Stage 2-4

90.10% (91)

54.76% (213)

59.04% (111)

Stage 0-1

13.16% (10)

56.96% (176)

57.04% (77)

Stage 4

86.84% (66)

43.04% (133)

42.96% (58)

P-value

P-value

NUMC vs. NSUH

NUMC vs. LIJ

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United States.
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Table 3. Sample of Those With Squamous Cell Carcinoma

Variable

NUMC % (#)

NSUH % (#)

LIJ % (#)

Stage 0-1

7.14% (4)

37.88% (50)

39.33% (35)

Stage 2-3

41.07% (23)

36.36% (48)

32.58% (29)

Stage 4

51.79% (29)

25.76% (34)

28.09% (25)

Stage 0-1

7.14% (4)

37.88% (50)

39.33% (35)

Stage 2-4

92.86% (52)

62.12% (82)

60.67% (54)

Stage 0-1

12.12% (4)

59.52% (50)

58.33% (35)

Stage 4

87.88% (29)

40.48% (34)

41.67% (25)

P-value

P-value

NUMC vs. NSR

NUMC vs. LIJ

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

NUMC: Nassau University Medical Center; NSUH: North Shore University Hospital; LIJ: Long Island Jewish; US: United
States. Note: Fisher’s exact test analyses used due to small sample size for NUMC.

size for a cell of less than 5 and where the Fisher’s exact test
was used. For the US national data (year 2006), the statistical assumption of independence was slightly relaxed as it is
possible that these US data also included the individuals in
the NUMC data. Our primary analysis was to compare the
percentage for overall stage differences between the hospitals for non-small cell cancer. Stata Version 11 was used for
all analyses. All P-values were two sided.

Results
The eligible sample of those with non-small cell lung cancer included 1,602 individuals. This included 401 individuals from NUMC with 66.83% (n = 268) below age 70 and
33.17% (n = 133) age 70 and above; and 42.4% (n = 170)
females and 57.6% (n = 231) males. There were 403 individuals from LIJ with 46.65% (n = 188) below 70 years of age
and 53.35% (n = 215) 70 years and above; and 50.62% (n =
204) females, 49.38% and (n = 199) males. There were 798
individuals from NSUH (North Shore University Hospital)
with 48.62% (n = 388) below 70 years of age and 51.38% (n
= 410) 70 years of age and above and 54.69% (n = 437) females, 45.31% and (n = 361) males. The sample sizes shown
100

in the results section slightly differ for certain analyses due
to omission of those with unknown or missing data.
Table 1 and Figure 1 show data for non-small cancers by
stage. In the three-level analyses of stage groups of 0-1, 2-3,
and 4, NUMC had an overall statistical significance for separate comparisons to NSUH, LIJ, and the US national sample.
These analyses showed much lower percentages of stage 0-1
for NUMC as compared to the other sites, mixed results for
stage 2-3 with higher percentages for NUMC as compared
to NSUH and LIJ but lower than the US national sample
and higher percentages for stage 4 as compared to NSUH,
LIJ, and the US national sample. The stage 4 percentages
for NUMC were at least 20% greater as compared to NSUH,
LIJ, and the US national sample (Fig. 1).
In Table 1, two additional analyses were performed
with only two-level analyses of stage groups. One approach
grouped stages 2-4 together and the other excluded stages 2-3
from the analyses. In the analyses with stages 2-4 grouped
together, NUMC had significantly lower percentages of
stage 0-1 as compared to stages 2-4 for separate comparisons
to NSUH, LIJ, and the US national sample. This ranged from
18% lower for the US national sample and more than 25%
lower than the NSUH and LIJ samples. In the analyses that
excluded stages 2-3 from the analyses, NUMC had signifi-
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cantly greater percentages of those with stage 4 as compared
to stages 0-1 for separate comparisons to NSUH, LIJ, and the
US national sample. This was more than 25% greater than
the US national sample and more than 35% greater than the
NSUH and LIJ samples.
Table 2 shows data for adenocarcinoma by stage. In the
three-level analyses of stage groups of 0-1, 2-3, and 4, NUMC
had an overall statistical significance for separate comparisons to NSUH and LIJ. These analyses showed much lower
percentages of stage 0-1 for NUMC as compared to NSUH
and LIJ, mixed results for stage 2-3 with higher percentages
for NUMC as compared to NSUH but lower than LIJ and
higher percentages for stage 4 as compared to NSUH and
LIJ. The stage 4 percentages for NUMC were at least 30%
greater as compared to the NSUH and LIJ samples.
In Table 2, two additional analyses were performed
with only two-level analyses of stage groups. One approach
grouped stages 2-4 together and the other excluded stages 2-3
from the analyses. In the analyses with stages 2-4 grouped
together, NUMC had significantly lower percentages of
stage 0-1 as compared to stages 2-4 for separate comparisons to NSUH and LIJ. This was at least 30% lower than the
NSUH and LIJ samples. In the analyses that excluded stages
2-3 from the analyses, NUMC had significantly greater percentages of those with stage 4 as compared to stages 0-1 for
separate comparisons to NSUH and LIJ. This was more than
40% greater than the NSUH and LIJ samples.
Table 3 shows data for squamous cell carcinoma by
stage. In the three-level analyses of stage groups of 0-1, 2-3,
and 4, NUMC had an overall statistical significance for separate comparisons to NSUH and LIJ. These analyses showed
much lower percentages of stage 0-1 for NUMC as compared
to the other sites, higher percentages for stage 2-3 for NUMC
as compared to NSUH and LIJ, and higher percentages for
stage 4 as compared to NSUH and LIJ. The stage 4 percentages for NUMC were at least 20% greater as compared to
NSUH and LIJ.
In Table 3, two additional analyses were performed
with only two-level analyses of stage groups. One approach
grouped stages 2-4 together and the other excluded stages 2-3
from the analyses. In the analyses with stages 2-4 grouped
together, NUMC had significantly lower percentages of
stage 0-1 as compared to stages 2-4 for separate comparisons to NSUH and LIJ. This was at least 30% lower than the
NSUH and LIJ samples. In the analyses that excluded stages
2-3 from the analyses, NUMC had significantly greater percentages of those with stage 4 as compared to stages 0-1 for
separate comparisons to NSUH and LIJ. This was more than
45% greater than the NSUH and LIJ samples.

Discussion
We found significant differences for lung cancer where

NUMC had greater percentages of stage 4 lung cancer and
lower percentages of stages 0-1 lung cancer as compared to
the two other local hospitals within the same health care system and the US national data. This was seen in non-small
cell cancers as well as adenocarcinoma and squamous cell
carcinoma. This is in contrast to an earlier study done in
Canada which did not show significant difference in stage at
diagnosis in different socioeconomic groups [6]. Apart from
this, there are multiple studies assessing impact of socioeconomic status generally on survival of cancer patients [7, 8]
Also, those at NUMC who were diagnosed with lung
cancer were relatively younger. This finding was independent of histology. We did not have enough numbers of adenosquamous, large cell carcinoma, carcinoid, and sarcomatoid cancers so we did not compare data for these cancers.
One of the most significant findings of this study was
that significantly less people with lung cancer were being
diagnosed in stage 1 at NUMC which caters to lower socioeconomic patients and a larger minority population as
compared to NSUH and LIJ which caters to predominantly
a more affluent section of the population and lesser minority
population. This has a very significant bearing on the mortality that lung cancer leads to as for practical purpose stages
0-1 are the only curable stage of lung cancer [5, 6]. This is
unfortunate, since despite appropriate diagnostic modalities considerable number of patients become fatal victims of
lung cancer because they are financially disadvantaged and
therefore may not come in contact with the health system as
frequently as they should.
This finding is very relevant in light of the recent study,
demonstrating reduction of mortality of lung cancer by low
dose CT scan for the first time in 30 years [3]. This has not
been made into a formal recommendation yet as debate is
going on, considering the costs the health care system would
incur to recommend CT scan for screening purpose and possible radiation concerns from CT scans. In view of above
findings we want to suggest that screening for lung cancer
in people of lower socioeconomic classes or minorities may
be useful. This topic should be considered as part of a riskbenefit analysis about screening benefits versus CT dose radiation long term side effects.
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